Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients [Phase 2]
Phase 2 study of ponatinib (Iclusig) to prevent relapse after allogeneic stem cell transplantation in FLT3-ITD acute myeloid leukemia has co…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS [Phase 1]
Phase 1, open-label study of intravenous GSK3745417 in relapsed/refractory myeloid malignancies (AML and high-risk myelodysplastic syndrome)…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Latin American Real-world Study in Acute Leukemia
Pfizer-sponsored Latin American real-world study in acute leukemia has completed with results publicly posted.
-
CLINICAL_TRIALS withdrawal · 2025-03-24Clinical Trial Update: DEC-C and Thioguanine for R/R AML [Phase 2]
A Phase 2 clinical trial evaluating DEC-C (decitabine/cedazuridine) and Thioguanine for relapsed/refractory acute myeloid leukemia has been …
-
CLINICAL_TRIALS research · 2025-03-24Clinical Trial Update: Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation [Phase 2]
Phase 2 clinical trial evaluating an anti-NKG2A monoclonal antibody in Acute Myeloid Leukemia or Myelodysplastic Syndromes patients undergoi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-03-24Clinical Trial Update: Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia [Phase 2]
Phase 2 clinical trial evaluating the addition of oral azacitidine to gilteritinib salvage therapy in adults with relapsed/refractory FLT3-m…
-
CLINICAL_TRIALS research · 2025-03-24Clinical Trial Update: Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy
A prospective epidemiological cohort study of patients aged 60 and older with acute myeloid leukemia undergoing intensive induction therapy,…
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia [Phase 1]
Phase 1 clinical trial evaluating UCMSC-Exo (umbilical cord mesenchymal stem cell-derived exosomes) to address chemotherapy-induced myelosup…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]
This Phase 2 trial investigates reduced-intensity chemotherapy and radiation therapy before donor stem cell transplantation for various hema…
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia [Phase 3]
A Phase 3 trial comparing oral decitabine/cedazuridine with azacitidine in myelodysplastic syndromes, acute myeloid leukemia with low blast …
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluating intensified dosing of idarubicin for acute myeloid leukemia to assess safety and efficacy.
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies [NA]
A clinical trial update examining whether CDA and/or dCK metabolizing enzymes influence the response to azacitidine in patients with hematol…
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients [NA]
A clinical trial is evaluating infusion of alloreactive natural killer (NK) cells in patients with acute myeloid leukemia who have minimal r…
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications [Phase 1, Phase 2]
A Phase 1/2 clinical trial of KPT-8602 (eltanexor) in participants with relapsed/refractory cancer indications completed, evaluating safety,…
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies [Phase 1, Phase 2]
Phase 1/2 study of FF-10501-01 in relapsed or refractory hematologic malignancies has completed, with results posted. The diseases studied i…
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Characterization of the Mechanisms of Resistance to Azacitidine
This clinical trial is investigating the mechanisms underlying resistance to azacitidine. It targets patients with myelodysplastic syndromes…
-
CLINICAL_TRIALS research · 2025-03-17Clinical Trial Update: A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML. [Phase 3]
Phase 3 randomized trial comparing two induction chemotherapy regimens for acute myeloid leukemia (HDAC vs AD), currently enrolling by invit…
-
CLINICAL_TRIALS research · 2025-03-17Clinical Trial Update: A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) [Phase 1]
A Phase 1 clinical trial evaluating STI-8591 in adults with advanced acute myeloid leukemia is currently recruiting.
-
CLINICAL_TRIALS research · 2025-03-17Clinical Trial Update: Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy [Phase 3]
Phase 3 clinical trial update comparing azacitidine plus pevonedistat versus azacitidine in patients with acute myeloid leukemia not eligibl…
-
CLINICAL_TRIALS research · 2025-03-17Clinical Trial Update: A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML [NA]
A single-arm prospective trial evaluating a conditioning regimen of total body irradiation (TBI) plus Busulfan-Melphalan (BUMEL) before salv…
-
CLINICAL_TRIALS trial_result · 2025-03-17Clinical Trial Update: Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia [NA]
A clinical trial evaluating autologous hematopoietic cell transplantation for core-binding factor acute myeloid leukemia; the study status i…
-
CLINICAL_TRIALS research · 2025-03-14Clinical Trial Update: Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML [Phase 1]
Phase 1 clinical trial exploring genetic ablation of CD33 in hematopoietic stem cells to broaden the therapeutic index of CD33-directed immu…
-
CLINICAL_TRIALS research · 2025-03-14Clinical Trial Update: Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy [Phase 2]
Phase 2 trial evaluating imetelstat in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia after failure of hypometh…
-
CLINICAL_TRIALS research · 2025-03-13Clinical Trial Update: Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients [Phase 3]
A Phase 3 trial is evaluating post-transplant cyclophosphamide as GVHD prophylaxis versus standard of care in acute leukemia patients in rem…
-
CLINICAL_TRIALS trial_result · 2025-03-13Clinical Trial Update: BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia [Phase 2]
Phase 2 randomized trial evaluating pembrolizumab added to azacitidine and venetoclax as frontline therapy for unfit acute myeloid leukemia …